Literature DB >> 7866567

Antigen expression associated with lymph node metastasis in gastric adenocarcinomas.

S N Wang1, M Miyauchi, N Koshikawa, K Maruyama, T Kubota, K Miura, Y Kurosawa, A Awaya, Y Kanai.   

Abstract

A total of 100 gastric adenocarcinomas, comprising 50 cases with lymph node metastasis and 50 cases without lymph node metastasis, were examined for immunohistochemical reactivity with the monoclonal antibody to urokinase-type plasminogen activator (u-PA), Lex related 4C9 antigen, Jun, or to nucleobindin (Nuc). In tumors with lymph node metastasis, 41 (82%) were positive for u-PA and 28 (56%) were positive for Nuc. In tumors without lymph node metastasis, 26 (52%) were positive for u-PA and five (10%) were positive for Nuc. The percentage of cases positive for u-PA or Nuc was significantly higher in tumors with lymph node metastasis than that in tumors without lymph node metastasis (P < 0.01). The expression of u-PA was found to be significantly correlated with that of Nuc (P < 0.001), mode of infiltrative growth (P < 0.05), depth of invasion (P < 0.01), and grade of lymphatic invasion (P < 0.01). However, the expression of Nuc was found to be significantly correlated with the expression of Jun (P < 0.05), depth of invasion (P < 0.01), and grade of lymphatic invasion (P < 0.001). These results suggest that immunohistochemical examination for the expression of u-PA and Nuc in tumor cells may help evaluate the potential of adenocarcinomas of the stomach for lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7866567     DOI: 10.1111/j.1440-1827.1994.tb01682.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  Nucleobindin 1 is a calcium-regulated guanine nucleotide dissociation inhibitor of G{alpha}i1.

Authors:  Neeraj Kapoor; Ruchi Gupta; Santosh T Menon; Ewa Folta-Stogniew; Daniel P Raleigh; Thomas P Sakmar
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

2.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

3.  A novel endoplasmic reticulum export signal: proline at the +2-position from the signal peptide cleavage site.

Authors:  Yoshinori Tsukumo; Satomi Tsukahara; Sakae Saito; Takashi Tsuruo; Akihiro Tomida
Journal:  J Biol Chem       Date:  2009-08-05       Impact factor: 5.157

4.  Nesfatin-1-like peptide is a novel metabolic factor that suppresses feeding, and regulates whole-body energy homeostasis in male Wistar rats.

Authors:  Kavishankar Gawli; Naresh Ramesh; Suraj Unniappan
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

5.  The mammalian calcium-binding protein, nucleobindin (CALNUC), is a Golgi resident protein.

Authors:  P Lin; H Le-Niculescu; R Hofmeister; J M McCaffery; M Jin; H Hennemann; T McQuistan; L De Vries; M G Farquhar
Journal:  J Cell Biol       Date:  1998-06-29       Impact factor: 10.539

6.  Nucleobindin co-localizes and associates with cyclooxygenase (COX)-2 in human neutrophils.

Authors:  Patrick Leclerc; Jordane Biarc; Mireille St-Onge; Caroline Gilbert; Andrée-Anne Dussault; Cynthia Laflamme; Marc Pouliot
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

7.  Quantitative proteomic analysis reveals that Luks-PV exerts antitumor activity by regulating the key proteins and metabolic pathways in HepG2 cells.

Authors:  Chang-Cheng Zhao; Wen-Wei Yu; Ying-Jie Qi; Liang-Fei Xu; Zi-Ran Wang; Ya-Wen Qiang; Fan Ma; Xiao-Ling Ma
Journal:  Anticancer Drugs       Date:  2020-03       Impact factor: 2.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.